14.25
                                            Schlusskurs vom Vortag:
              $14.64
            Offen:
              $14.36
            24-Stunden-Volumen:
                48,474
            Relative Volume:
              0.52
            Marktkapitalisierung:
                $390.38M
            Einnahmen:
              -
            Nettoeinkommen (Verlust:
              $-102.09M
            KGV:
              -13.57
            EPS:
                -1.05
            Netto-Cashflow:
                $-108.72M
            1W Leistung:
              -10.88%
            1M Leistung:
              +10.47%
            6M Leistung:
                +59.22%
            1J Leistung:
              +274.41%
            Dbv Technologies Adr Stock (DBVT) Company Profile
Firmenname
                  
                      Dbv Technologies Adr
                    
                Sektor
                  Branche
                  Telefon
                  
                      33(0)155427878
                    
                Adresse
                  
                      107 AVENUE DE LA REPUBLIQUE, CHATILLON
                    
                Vergleichen Sie DBVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                DBVT
                            
                             
                        Dbv Technologies Adr 
                           | 
                    14.25 | 494.70M | 0 | -102.09M | -108.72M | -1.05 | 
| 
                         
                          
                                VRTX
                            
                             
                        Vertex Pharmaceuticals Inc 
                           | 
                    426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 | 
| 
                         
                          
                                REGN
                            
                             
                        Regeneron Pharmaceuticals Inc 
                           | 
                    642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 | 
| 
                         
                          
                                ALNY
                            
                             
                        Alnylam Pharmaceuticals Inc 
                           | 
                    434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 | 
| 
                         
                          
                                ARGX
                            
                             
                        Argen X Se Adr 
                           | 
                    826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 | 
| 
                         
                          
                                INSM
                            
                             
                        Insmed Inc 
                           | 
                    186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 | 
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2025-05-29 | Fortgesetzt | Goldman | Sell | 
| 2023-01-04 | Hochstufung | Societe Generale | Hold → Buy | 
| 2022-12-16 | Herabstufung | Goldman | Neutral → Sell | 
| 2022-05-10 | Herabstufung | Goldman | Buy → Neutral | 
| 2021-09-14 | Hochstufung | Societe Generale | Hold → Buy | 
| 2021-01-22 | Herabstufung | Societe Generale | Hold → Sell | 
| 2020-11-02 | Hochstufung | Societe Generale | Sell → Hold | 
| 2020-08-06 | Herabstufung | Societe Generale | Buy → Sell | 
| 2020-08-05 | Bestätigt | H.C. Wainwright | Buy | 
| 2020-03-17 | Herabstufung | Stifel | Buy → Hold | 
| 2020-01-09 | Hochstufung | Stifel | Hold → Buy | 
| 2019-12-16 | Eingeleitet | Citigroup | Buy | 
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight | 
| 2019-06-17 | Eingeleitet | Goldman | Buy | 
| 2018-12-20 | Herabstufung | Barclays | Overweight → Equal Weight | 
| 2018-12-20 | Herabstufung | BofA/Merrill | Buy → Underperform | 
| 2018-12-20 | Herabstufung | Jefferies | Buy → Hold | 
| 2018-12-20 | Herabstufung | Stifel | Buy → Hold | 
| 2017-10-31 | Hochstufung | Societe Generale | Sell → Hold | 
| 2017-10-24 | Herabstufung | Societe Generale | Buy → Sell | 
| 2017-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight | 
| 2017-06-23 | Eingeleitet | Deutsche Bank | Buy | 
| 2017-03-16 | Hochstufung | Societe Generale | Hold → Buy | 
| 2016-09-26 | Eingeleitet | JMP Securities | Mkt Outperform | 
| 2015-12-03 | Eingeleitet | Barclays | Overweight | 
| 2015-10-23 | Eingeleitet | BofA/Merrill | Buy | 
                    Alle ansehen
                    
                  
                Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - 24matins.uk
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Appoints Dr. Philina Lee to Board - TipRanks
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies (NASDAQ: DBVT) appoints Philina Lee to Board as independent director - Stock Titan
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
Health Care And Telecom Drive European ADR Gains In The US - Finimize
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
DBV Technologies Reports Third Quarter 2025 Financial Results - TradingView
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Healthcare And Biotech Led European ADRs As Markets Steadied - Finimize
Optimistic Outlook for DBV Technologies Amid Promising Viaskin Peanut Advancements - TipRanks
European ADRs Edge Higher As Healthcare Leads Gains - Finimize
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? - Yahoo Finance
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Orion, Nio, Alibaba Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Pre-market Movers: GNPX, BFRI, DBVT See Big Swings - RTTNews
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages - Defense World
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving PremarketAehr Test System (NASDAQ:AEHR), Amkor Tech (NASDAQ:AMKR) - Benzinga
DBV Technologies raises $30 million through ADS sale on Nasdaq - Investing.com
$30M ADS Sale: DBV Technologies Issues 2,307,692 ADSs via ATM Program on Nasdaq and Euronext Paris - Stock Titan
Biotech Stocks Lead European ADRs Higher On Wall Street - Finimize
European Biotech Stocks Outperformed As Broader Market Dipped - Finimize
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
DBV Technologies Announces Board Member Resignation - MSN
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
European ADRs In The US See Modest Gains On Health And Tech - Finimize
What drives DBV Technologies SA DBV stock priceLarge Cap Stability Picks & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
Can DBV Technologies S.A. Depositary Receipt stock reach $100 price target2025 Market Trends & Expert Curated Trade Ideas - newser.com
DBV Technologies Announces Resignation of Board Member - GlobeNewswire
Biotech Board Shake-up: DBV Technologies Director Exits Amid VIASKIN Peanut Patch Development - Stock Titan
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
DBV Technologies stock rating reiterated at Market Outperform by JMP - Investing.com
Finanzdaten der Dbv Technologies Adr-Aktie (DBVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):